HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.

AuthorsChristina Gross, Anwesha Banerjee, Durgesh Tiwari, Francesco Longo, Angela R White, A G Allen, Lindsay M Schroeder-Carter, Joseph C Krzeski, Nada A Elsayed, Rosemary Puckett, Eric Klann, Ralph A Rivero, Shannon L Gourley, Gary J Bassell
JournalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology) Vol. 47 Issue 9 Pg. 1733 (Aug 2022) ISSN: 1740-634X [Electronic] England
PMID35701551 (Publication Type: Published Erratum)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: